Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Also Read: Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Johnson & Johnson (NYSE:JNJ) Stock Price Up 0.7% After Analyst Upgrade Mi Christoph Geyer: Gelassene Perspektive auf den KI-Sputnik-Moment, Nvidia, DAX neuer Rekord, SPX, Rheinmetall, J&J, D. Börse ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).